Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist developed by Altimmune (now acquired by Novo Nordisk’s obesity pipeline network). Unlike single-target GLP-1 agonists such as semaglutide, pemvidutide simultaneously activates both the GLP-1 receptor and the glucagon receptor, aiming to combine appetite suppression with glucagon-mediated increases in energy expenditure and hepatic fat reduction.[1][2]

Pemvidutide has generated significant clinical interest through phase 2 trials in both obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), with the Lancet publishing results from the IMPACT trial in December 2025. The dual-agonist approach positions pemvidutide alongside tirzepatide (GIP/GLP-1) and retatrutide (GLP-1/GIP/glucagon) as part of the multi-receptor agonist class.[1][3]

Compound Profile

What Does Pemvidutide Actually Do?

Pemvidutide combines two pharmacological actions through dual receptor activation. GLP-1R agonism suppresses appetite and improves glycaemic control (the mechanism shared with semaglutide), while glucagon receptor agonism increases hepatic lipid oxidation, energy expenditure, and preferentially reduces liver fat.[1][2]

The IMPACT phase 2b trial published in The Lancet demonstrated that pemvidutide achieved significant weight loss and improvements in hepatic steatosis in patients with MASH. At 24 weeks, pemvidutide produced clinically meaningful reductions in liver fat content and improvements in markers of liver fibrosis — addressing a disease where effective pharmacological treatments remain limited.[1]

How Pemvidutide Works

Pemvidutide’s dual mechanism creates complementary metabolic effects through two distinct receptor pathways:[2][3]

GLP-1 receptor activation: Reduces appetite through hypothalamic signalling, enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes satiety. This component drives the weight loss and glycaemic improvement seen with all GLP-1 agonists.

Glucagon receptor activation: Stimulates hepatic fatty acid oxidation and ketogenesis, increases resting energy expenditure, and promotes liver fat mobilisation. Glucagon’s catabolic effects on liver fat complement GLP-1’s appetite-suppressive effects, potentially producing greater hepatic steatosis reduction than GLP-1 agonism alone.

The rationale for dual agonism is that glucagon’s metabolic effects — increased energy expenditure and liver fat reduction — address aspects of metabolic disease that GLP-1 agonism alone does not optimally target. The challenge is balancing glucagon’s hyperglycaemic effects with GLP-1’s glucose-lowering activity, which pemvidutide achieves through calibrated receptor activation ratios.

Pemvidutide’s once-weekly injection profile is achieved through fatty acid acylation (similar to semaglutide’s albumin-binding approach), extending plasma half-life through reversible albumin binding.

Appetite & Weight Management Context

Pemvidutide’s clinical data positions it within the appetite and weight management research landscape as a next-generation multi-agonist. Phase 2 obesity trial data showed significant weight loss, with the dual GLP-1/glucagon mechanism theoretically offering advantages over pure GLP-1 agonism through additional energy expenditure stimulation.[2][4]

A key question is whether the glucagon component provides meaningful additional weight loss beyond what GLP-1 agonism alone achieves. Early data suggests the contribution is present but modest compared to the appetite-suppressive effects of GLP-1R activation. The primary differentiator may be body composition — glucagon’s preferential mobilisation of liver and visceral fat could produce metabolically superior weight loss even at similar total weight reduction.[1]

Compare with semaglutide (GLP-1 only), tirzepatide (GIP/GLP-1), and retatrutide (triple GLP-1/GIP/glucagon), or see the Appetite & Weight Management goal page.

Metabolic Health / Insulin Sensitivity Context

The MASH indication places pemvidutide squarely within the metabolic health context. MASH — the inflammatory stage of fatty liver disease — has no approved pharmacological cure, making effective treatments a major unmet medical need. Pemvidutide’s glucagon-mediated liver fat reduction directly targets the pathological process driving MASH progression.[1][3]

The Lancet-published IMPACT trial demonstrated significant reductions in hepatic steatosis and improvements in fibrosis markers at 24 weeks. A GRADE-assessed meta-analysis confirmed pemvidutide’s efficacy and safety profile in the MASH population, providing systematic evidence synthesis beyond individual trial results.[5]

Glycaemic effects reflect the balanced dual agonism — GLP-1’s glucose-lowering activity offsets glucagon’s hyperglycaemic tendency, resulting in net-neutral to mildly improved glucose control in most patients. See the Metabolic Health goal page for broader context.

Fat Loss & Recomp Context

Pemvidutide’s glucagon component adds a fat loss-relevant dimension beyond pure appetite suppression. Glucagon receptor activation stimulates hepatic lipid oxidation and increases resting energy expenditure, potentially producing preferential fat mass reduction compared to agents that reduce weight primarily through caloric restriction.[2]

Concerns about muscle loss during pharmacological weight loss have been raised across the GLP-1 agonist class. Whether pemvidutide’s dual mechanism produces a more favourable fat-to-lean mass loss ratio compared to GLP-1-only agents is an active research question. The increased energy expenditure from glucagon agonism theoretically favours fat oxidation, but clinical body composition data is limited.[6]

See the Fat Loss & Recomp goal page for broader context.

Pemvidutide Benefits

• Dual mechanism: Simultaneous GLP-1 and glucagon receptor activation provides complementary metabolic effects — appetite suppression plus increased energy expenditure and liver fat reduction.[1][2]
• Lancet-published MASH data: Phase 2b results in MASH showed significant hepatic steatosis reduction and fibrosis improvement — addressing a major unmet medical need.[1][3]
• Weekly injection: Once-weekly subcutaneous dosing provides convenient administration comparable to semaglutide.
• Preferential liver fat reduction: Glucagon-mediated hepatic lipid oxidation may produce metabolically superior outcomes compared to weight loss from appetite suppression alone.[2]
• Energy expenditure increase: Glucagon agonism stimulates resting energy expenditure, a mechanism not present in pure GLP-1 agonists.[2]

Pemvidutide Side Effects

Phase 2 clinical trial data provides safety characterisation:

• Gastrointestinal effects: Nausea, vomiting, and diarrhoea were the most common adverse events — consistent with the GLP-1 agonist class. Rates were generally manageable with dose titration.
• Appetite reduction: Significant appetite suppression, while therapeutically desirable, can be excessive at higher doses.
• Glycaemic effects: The glucagon component’s hyperglycaemic tendency is partially offset by GLP-1’s glucose-lowering effect, but monitoring is needed in diabetic patients.
• Heart rate effects: Small increases in heart rate have been observed, consistent with GLP-1 agonist class effects.
• Limited long-term data: Phase 2 trial durations (24 weeks) do not capture potential long-term safety signals.

Half-Life

Pemvidutide has a plasma half-life supporting once-weekly subcutaneous injection, achieved through fatty acid acylation that promotes reversible albumin binding in circulation. This pharmacokinetic approach is analogous to the half-life extension strategy used in semaglutide. Exact half-life values from pharmacokinetic studies have been characterised in the clinical pharmacokinetics literature.[7]

Limits of Current Evidence

• No phase 3 data: While phase 2b results are promising and Lancet-published, phase 3 trials are needed for regulatory submission and to confirm findings in larger populations.
• Short trial duration: 24-week data does not capture durability of effect, potential for treatment resistance, or long-term safety.
• Body composition data limited: Whether the glucagon component truly produces superior fat-to-lean mass loss ratios requires more detailed body composition studies.[6]
• Competitive landscape pressure: Pemvidutide enters a rapidly expanding market with semaglutide, tirzepatide, and retatrutide — distinguishing itself commercially requires clear clinical advantages.
• MASH endpoint debate: Surrogate endpoints (liver fat, fibrosis markers) used in phase 2 MASH trials may not predict hard clinical outcomes (cirrhosis prevention, liver transplant reduction).

Verdict

Pemvidutide occupies a compelling position in the multi-agonist peptide landscape — a dual GLP-1/glucagon agonist with Lancet-published phase 2b data in one of medicine’s most significant unmet needs (MASH). The glucagon component provides a pharmacologically rational addition to GLP-1 agonism, targeting liver fat metabolism and energy expenditure in ways that single-target agents do not.

The clinical evidence supports both weight management and hepatic steatosis applications, with the MASH indication arguably offering the clearest competitive differentiation. Whether pemvidutide can secure a distinct clinical niche against the formidable competition from tirzepatide and retatrutide depends on phase 3 results, particularly in MASH-specific hard endpoints and body composition outcomes.

FAQ

What is pemvidutide?

Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist — a once-weekly injectable peptide that simultaneously activates both the GLP-1 receptor (reducing appetite) and the glucagon receptor (increasing energy expenditure and liver fat oxidation). It has completed phase 2b trials in obesity and MASH.

How does pemvidutide differ from semaglutide?

Semaglutide activates only the GLP-1 receptor. Pemvidutide activates both GLP-1 and glucagon receptors. The glucagon component adds hepatic fat reduction and increased energy expenditure — effects not produced by GLP-1 agonism alone. Both are once-weekly injectable peptides.

What is pemvidutide used for?

Pemvidutide is being investigated for obesity/weight management and for metabolic dysfunction-associated steatohepatitis (MASH/NASH). The Lancet-published IMPACT trial focused on the MASH indication, showing significant liver fat reduction and fibrosis improvement. Pemvidutide is not yet approved for any indication.

What are pemvidutide side effects?

The most common side effects in clinical trials were gastrointestinal (nausea, vomiting, diarrhoea) — consistent with GLP-1 agonist class effects. Small heart rate increases and appetite reduction were also observed. Long-term safety beyond 24 weeks has not been characterised.

Is pemvidutide approved?

No. Pemvidutide has completed phase 2b clinical trials but has not been approved by any regulatory agency. Phase 3 trials would be needed for regulatory submission. Results from the IMPACT trial were published in The Lancet in December 2025.

How does pemvidutide compare to tirzepatide?

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist, while pemvidutide is a dual GLP-1/glucagon agonist. They use different second receptors: tirzepatide adds GIP (which enhances insulin secretion), pemvidutide adds glucagon (which increases energy expenditure and liver fat oxidation). Tirzepatide is approved and has more extensive clinical data.

References

1. Noureddin M, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results of a randomised, double-blind, phase 2b trial. Lancet. 2025. PMID: 41237796
2. Anderson SL, et al. Emerging concepts in obesity management: focus on pemvidutide. Drugs Context. 2025. PMID: 40734920
3. Tacke F, et al. The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. Lancet. 2025. PMID: 41352959
4. Harrison SA, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025. PMID: 39002641
5. Rajab I, et al. Efficacy and safety of pemvidutide in MASH: a GRADE-assessed meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID: 41879841
6. von Haehling S, et al. Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions. J Cachexia Sarcopenia Muscle. 2025. PMID: 41362110
7. Nordell P, et al. Systemic Pharmacokinetic Principles of Therapeutic Peptides. Clin Pharmacokinet. 2026. PMID: 41661442

Survodutide (also known by its development code BI 456906) is a GLP-1/glucagon dual agonist peptide designed by Zealand Pharma and developed clinically by Boehringer Ingelheim. Unlike single-target GLP-1 receptor agonists such as semaglutide or liraglutide, the survodutide peptide simultaneously activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).

This dual-receptor approach is specifically intended to address conditions where appetite suppression alone is insufficient. The glucagon component of survodutide targets the liver directly, promoting hepatic fat oxidation and increasing energy expenditure — mechanisms that are particularly relevant for MASLD (metabolic dysfunction-associated steatotic liver disease) and its progressive form, MASH.

The survodutide Boehringer development programme has progressed rapidly, receiving FDA Breakthrough Therapy Designation for MASH. The compound is administered as a once-weekly subcutaneous injection with an estimated half-life of approximately 60–70 hours.

Compound Profile

Mechanism of Action

Survodutide’s mechanism relies on the coordinated activation of two receptor systems, each contributing distinct metabolic effects.

GLP-1 receptor activation drives appetite suppression, slowed gastric emptying, and improved glucose-dependent insulin secretion. These are the same pathways targeted by established GLP-1 receptor agonists used in appetite and weight management.

Glucagon receptor activation adds a differentiated dimension. Glucagon signalling in the liver increases hepatic fat oxidation, promotes glycogenolysis, and elevates resting energy expenditure. Preclinical pharmacology studies demonstrated that the survodutide glucagon component is essential for the compound’s superior weight loss and metabolic effects beyond what GLP-1 activation alone achieves. A 2025 preclinical study confirmed that hepatic GCGR activation is specifically required for the enhanced weight loss and metabolic improvements observed with this GLP-1 glucagon dual agonist class.

This dual-agonist design positions survodutide as more than a weight loss drug. The glucagon-mediated liver effects make it a potentially first-in-class treatment for MASH — a condition characterised by fat accumulation, inflammation, and fibrosis in the liver for which limited pharmacological options currently exist.

Zealand Pharma engineered the peptide backbone to achieve balanced potency at both receptors, while Boehringer Ingelheim has led the clinical development programme. Biomarker and pharmacological profiling studies have characterised survodutide’s receptor engagement, confirming robust dual activation at clinically relevant exposures.

MASLD / MASH Clinical Evidence

The most compelling clinical data for survodutide comes from its Phase 2 trial in MASH, published in the New England Journal of Medicine in 2024.

In this randomised, placebo-controlled study, participants with biopsy-confirmed MASH and liver fibrosis (stages F1–F3) received survodutide at escalating doses for 48 weeks. The results were striking:

• 83% resolution of steatohepatitis without worsening of fibrosis at the highest dose group — compared to 18.2% in the placebo arm
• Significant fibrosis improvement by at least one stage in a substantial proportion of treated participants
• Marked reductions in liver fat content as measured by MRI-derived proton density fat fraction
• Dose-dependent improvements in liver biomarkers including ALT and AST

These survodutide MASLD results represent some of the most robust liver-specific outcomes seen with any incretin-based therapy to date. The survodutide liver benefits are thought to derive primarily from the glucagon receptor component, which directly promotes hepatic fat oxidation — an effect that pure GLP-1 agonists do not replicate as effectively.

A separate Phase 1 study evaluated survodutide in patients with compensated cirrhosis (Child-Pugh A), confirming acceptable tolerability and pharmacokinetic profiles in this more advanced liver disease population.

Weight Loss Data

Survodutide weight loss data from Phase 2 trials has demonstrated clinically meaningful results across multiple study populations.

In the pivotal Phase 2 obesity trial published in The Lancet Diabetes & Endocrinology, adults with obesity (BMI ≥30, or ≥27 with comorbidities) received survodutide at various doses for 46 weeks:

• The highest dose group achieved mean weight loss of up to 18.7% of baseline body weight
• Weight reductions were dose-dependent and progressive throughout the treatment period
• Survodutide demonstrated weight loss comparable to or exceeding that observed with open-label semaglutide 2.4 mg in the same study

In a separate Phase 2 trial in people with type 2 diabetes, survodutide produced significant HbA1c reductions alongside meaningful weight loss, with dose-response effects observed across treatment arms. The dual mechanism — combining appetite suppression through GLP-1R with increased energy expenditure through GCGR — likely contributes to the magnitude of weight reduction achieved.

A 2025 systematic review and meta-analysis pooling data across survodutide trials confirmed consistent efficacy on both glycaemic control and weight loss in adults, with effect sizes that position it competitively among next-generation incretin-based therapies for fat loss.

Metabolic Effects

Beyond weight and liver outcomes, survodutide has demonstrated broad metabolic benefits in clinical trials:

Glycaemic control: In the Phase 2 type 2 diabetes study, survodutide GLP-1 and glucagon co-activation produced dose-dependent reductions in HbA1c, with the highest doses achieving reductions that were clinically comparable to established GLP-1 agonists. The dual mechanism may offer an advantage in patients with both obesity and diabetes, where glucagon’s effects on hepatic glucose output are balanced by the insulin-sensitising effects of weight loss and GLP-1R activation.

Lipid metabolism: Clinical data indicates improvements in triglyceride levels and other lipid parameters, consistent with the expected effects of both weight reduction and enhanced hepatic fat oxidation mediated by glucagon signalling.

Insulin sensitivity: Weight loss of the magnitude seen with survodutide (up to 18.7%) would be expected to produce meaningful improvements in insulin sensitivity, though dedicated insulin clamp studies have not been published at the time of writing.

Cardiovascular biomarkers: The SYNCHRONIZE cardiovascular outcomes trial (CVOT) has been designed to evaluate survodutide’s effects on major adverse cardiovascular events in people with obesity, reflecting the expectation that its metabolic benefits may translate to cardiovascular risk reduction.

Safety and Side Effects

The survodutide side effects profile observed across Phase 1 and Phase 2 trials is broadly consistent with the GLP-1 receptor agonist class, with gastrointestinal events representing the most common adverse effects.

Common side effects reported in clinical trials:

• Nausea — the most frequently reported adverse event, typically mild to moderate and most common during dose escalation
• Vomiting — also most prevalent during the titration phase
• Diarrhoea — occurring at rates similar to other GLP-1-based therapies
• Decreased appetite — generally considered a therapeutic effect rather than a side effect
• Constipation — reported by a minority of participants

Tolerability considerations: The Phase 1 programme established that a gradual dose-escalation strategy meaningfully reduces the incidence and severity of gastrointestinal side effects. Most adverse events were transient and diminished with continued treatment.

Glucagon-specific safety signals: Because survodutide activates the glucagon receptor, there is theoretical concern about hyperglycaemia. However, clinical data suggests that the GLP-1 component effectively counterbalances glucagon’s glycaemic effects, and no clinically significant hyperglycaemia has been reported in trials. Mild, transient increases in heart rate were observed in some dose groups, consistent with GLP-1 receptor agonist pharmacology.

The Phase 1 study in Japanese men with overweight/obesity confirmed a similar safety profile, supporting the generalisability of these findings across populations.

SYNCHRONIZE Phase 3 Programme

The survodutide Phase 3 clinical development programme, branded SYNCHRONIZE, represents one of the most ambitious Phase 3 programmes in the incretin space. It includes multiple pivotal trials:

SYNCHRONIZE-1: Phase 3 trial evaluating survodutide for weight management in adults with obesity without type 2 diabetes.

SYNCHRONIZE-2: Phase 3 trial in adults with obesity and type 2 diabetes. Published baseline characteristics confirm a large, multinational study population designed to support regulatory approval.

SYNCHRONIZE-CVOT: A cardiovascular outcomes trial assessing whether survodutide reduces major adverse cardiovascular events in people with established cardiovascular disease and obesity. The trial design, published in JACC: Heart Failure, reflects the regulatory expectation for cardiovascular safety and efficacy data.

SYNCHRONIZE-MASH: Phase 3 trials in MASH, building on the strong Phase 2 results. The FDA’s Breakthrough Therapy Designation for the MASH indication underscores the unmet medical need and the strength of existing clinical evidence.

If successful, the SYNCHRONIZE programme could position survodutide Boehringer Ingelheim as a first-in-class treatment for MASH and a competitive option for obesity — potentially differentiating it from the crowded GLP-1 agonist field through its liver-focused mechanism.

Research Limitations

While the survodutide evidence base is promising, several important limitations should be acknowledged:

• No Phase 3 efficacy data published yet: The strongest clinical evidence comes from Phase 2 trials. Phase 3 results from the SYNCHRONIZE programme are anticipated but not yet available. Phase 2 effect sizes do not always replicate in larger Phase 3 populations.
• Limited long-term safety data: The longest published treatment duration is 48 weeks. Long-term safety beyond one year — including effects on bone density, lean mass preservation, and potential thyroid signals — remains unknown.
• Histological endpoints require confirmation: The MASH Phase 2 trial used liver biopsy endpoints, which are the gold standard but involve inherent sampling variability. Phase 3 confirmation with larger sample sizes is needed.
• Glucagon-specific risks are not fully characterised: The long-term metabolic consequences of chronic glucagon receptor activation — including potential effects on amino acid metabolism, hepatic protein synthesis, and adrenal function — require further investigation.
• Head-to-head comparisons are limited: Direct comparisons with semaglutide exist only in a Phase 2 type 2 diabetes trial. No head-to-head data exists against tirzepatide, retatrutide, or resmetirom (the only currently approved MASH treatment).
• Population generalisability: Most trial participants were from Western populations. The Phase 1 Japanese study provides some cross-population data, but broader diversity is needed.

Verdict

Survodutide is one of the most promising peptides in the metabolic disease pipeline. Its GLP-1/glucagon dual agonist mechanism offers a differentiated approach that goes beyond appetite suppression — directly targeting the liver through glucagon receptor activation to promote hepatic fat clearance and increase energy expenditure.

The Phase 2 MASH results, with 83% steatohepatitis resolution, represent potentially best-in-class liver outcomes among incretin-based therapies. Combined with weight loss of up to 18.7% and meaningful glycaemic improvements, survodutide addresses the interconnected pathology of obesity, type 2 diabetes, and fatty liver disease.

However, evidence confidence remains moderate. Phase 3 data from the SYNCHRONIZE programme will be the decisive factor in determining whether survodutide’s Phase 2 promise translates to regulatory approval and clinical use. The compound’s safety profile appears manageable but requires longer-term characterisation, and head-to-head trials against established competitors would strengthen its positioning.

For researchers and clinicians tracking the next generation of metabolic therapies, survodutide — alongside retatrutide and tirzepatide — represents a meaningful evolution beyond first-generation GLP-1 agonists, with the liver-focused mechanism being its most compelling differentiator.

FAQ

What is survodutide?

Survodutide (BI 456906) is a GLP-1/glucagon dual agonist peptide developed by Boehringer Ingelheim in partnership with Zealand Pharma. It activates both the GLP-1 receptor and the glucagon receptor, combining appetite suppression with increased hepatic fat oxidation and energy expenditure. It is currently in Phase 3 clinical trials for obesity and MASH.

How does survodutide differ from semaglutide?

While semaglutide is a pure GLP-1 receptor agonist, survodutide is a GLP-1 glucagon dual agonist that also activates the glucagon receptor. This additional glucagon component promotes direct hepatic fat burning and increases resting energy expenditure — mechanisms not present with semaglutide. This makes survodutide particularly relevant for liver diseases like MASLD and MASH.

What are the main survodutide side effects?

The most commonly reported survodutide side effects in clinical trials are gastrointestinal in nature: nausea, vomiting, diarrhoea, and decreased appetite. These are generally mild to moderate, most common during dose escalation, and tend to diminish with continued treatment. The safety profile is broadly similar to other GLP-1-based therapies.

What were the survodutide MASH trial results?

In the Phase 2 MASH trial published in the New England Journal of Medicine, survodutide achieved 83% resolution of steatohepatitis at the highest dose, compared to 18.2% with placebo. Significant improvements in fibrosis stage and liver fat content were also observed, representing some of the strongest liver-specific results for any incretin-based therapy.

How much weight loss does survodutide produce?

In the Phase 2 obesity trial, participants receiving the highest dose of survodutide achieved mean weight loss of up to 18.7% of baseline body weight over 46 weeks. Weight loss was dose-dependent and comparable to or exceeding open-label semaglutide 2.4 mg in the same study.

What is the SYNCHRONIZE programme?

SYNCHRONIZE is the survodutide Phase 3 clinical development programme run by Boehringer Ingelheim. It includes separate pivotal trials for obesity (with and without type 2 diabetes), MASH, and a cardiovascular outcomes trial. These trials will determine whether survodutide receives regulatory approval.

Is survodutide approved for clinical use?

No. As of early 2026, survodutide remains an investigational compound in Phase 3 trials. It has received FDA Breakthrough Therapy Designation for the MASH indication, but no regulatory approvals have been granted. Phase 3 results are anticipated in the coming years.

What is the survodutide half-life?

Survodutide has an estimated half-life of approximately 60–70 hours, which supports once-weekly subcutaneous administration. This pharmacokinetic profile was established through Phase 1 clinical studies in both Western and Japanese populations.

How does survodutide compare to retatrutide?

Retatrutide is a triple agonist (GLP-1/GIP/glucagon) while survodutide is a dual agonist (GLP-1/glucagon only). Retatrutide has shown greater weight loss in Phase 2 (over 24%), but survodutide is further advanced in clinical development and has stronger published liver-specific data. Both share the glucagon component that differentiates them from GLP-1/GIP agonists like tirzepatide.

Who developed survodutide?

The survodutide peptide backbone was designed by Zealand Pharma, a Danish biotechnology company specialising in peptide therapeutics. Boehringer Ingelheim, a German pharmaceutical company, leads the clinical development programme and holds the global rights. The Boehringer Ingelheim survodutide programme is one of the largest in the company’s metabolic disease portfolio.

References

1. Zimmermann T et al. “BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.” Mol Metab, 2022. PubMed
2. Jungnik A et al. “Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.” Diabetes Obes Metab, 2023. PubMed
3. Blüher M et al. “Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.” Diabetologia, 2024. PubMed
4. le Roux CW et al. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” Lancet Diabetes Endocrinol, 2024. PubMed
5. Sanyal AJ et al. “A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.” N Engl J Med, 2024. PubMed
6. Lawitz EJ et al. “Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.” J Hepatol, 2024. PubMed
7. Thomas L et al. “The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.” Diabetes Obes Metab, 2024. PubMed
8. Kosiborod MN et al. “Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.” JACC Heart Fail, 2024. PubMed
9. Wharton S et al. “Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.” Diabetes Obes Metab, 2026. PubMed
10. Xiao YJ et al. “Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.” Diabetes Obes Metab, 2025. PubMed

If your query is what is retatrutide, the practical answer is: retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist — a single molecule that activates GLP-1, GIP, and glucagon receptors simultaneously. It represents the most aggressive multi-receptor approach to obesity and metabolic disease currently in clinical development, and its Phase 2 trial results (published in the New England Journal of Medicine) produced the largest weight reductions ever reported for any anti-obesity medication.[1][2]

Retatrutide was developed by Eli Lilly (the same company behind tirzepatide). While tirzepatide is a dual GIP/GLP-1 agonist, retatrutide adds glucagon receptor activation as a third mechanism — introducing direct metabolic effects including increased energy expenditure, enhanced hepatic fat oxidation, and thermogenesis that go beyond appetite suppression alone.[2][7]

The compound is currently in Phase 3 clinical trials (the TRIUMPH programme) across multiple indications: obesity, type 2 diabetes, obstructive sleep apnoea, and knee osteoarthritis. No GLP-1-class compound has entered Phase 3 with such strong weight loss signals from earlier-phase data.[1][6]

Compound Profile

What Does Retatrutide Actually Do?

Retatrutide produces weight loss and metabolic improvement through coordinated activation of three hormone receptors. The Phase 2 clinical results are unprecedented in the obesity pharmacotherapy field:[1][2]

• Weight loss (Phase 2, obesity): Jastreboff et al. (2023) demonstrated up to 24.2% mean body weight reduction at 48 weeks with retatrutide 12 mg in adults with obesity — the largest weight loss ever reported for any anti-obesity medication in a controlled trial. Published in the New England Journal of Medicine.[1]
• Weight loss in T2D: Rosenstock et al. (2023) showed retatrutide produced up to 16.9% body weight loss in patients with type 2 diabetes, alongside HbA1c reductions of up to 2.0%. Published in The Lancet.[2]
• Liver fat reduction (MASLD): Sanyal et al. (2024) demonstrated that retatrutide reduced liver fat by up to 82.4% from baseline over 48 weeks, with 93% of participants achieving the ≥30% reduction threshold associated with MASLD resolution. Published in Nature Medicine.[3]
• Body composition: Coskun et al. (2025) published a body composition substudy showing retatrutide produced substantial fat mass reduction. Published in Lancet Diabetes & Endocrinology.[5]
• Meta-analysis confirmation: Pasqualotto et al. (2024) conducted a systematic review and meta-analysis confirming retatrutide’s weight and metabolic benefits across available trials.[4]

How Retatrutide Works

Retatrutide’s triple agonist mechanism is what distinguishes it from all currently approved obesity treatments. Each receptor contributes distinct pharmacological effects:[7][8][9]

• GLP-1 receptor activation: reduces appetite through central hypothalamic and brainstem signalling, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the shared mechanism with semaglutide and liraglutide.[7][9]
• GIP receptor activation: potentiates the GLP-1-mediated appetite reduction and insulin secretion, while potentially improving fat tissue metabolism. This is the shared mechanism with tirzepatide (which is a dual GIP/GLP-1 agonist).[7][8]
• Glucagon receptor activation (unique to retatrutide): this is the critical differentiator. Glucagon receptor agonism increases hepatic fat oxidation, stimulates thermogenesis and energy expenditure, promotes amino acid catabolism, and reduces liver fat. Unlike GLP-1 and GIP (which primarily reduce caloric intake), glucagon receptor activation increases caloric output.[7][8][9]

The engineering insight: retatrutide doesn’t just suppress appetite more effectively — it adds an entirely new metabolic dimension. The glucagon component creates a “push-pull” effect: GLP-1 and GIP reduce energy intake, while glucagon increases energy expenditure. This dual mechanism likely explains the unprecedented weight loss results and the dramatic liver fat reductions seen in the MASLD trial.[1][3][7]

Coskun et al. (2022) published the preclinical discovery and development of LY3437943 in Cell Metabolism, establishing the pharmacological rationale for the triple agonist approach and demonstrating superior weight loss and metabolic improvement versus dual agonism in preclinical models.[7]

Appetite and Weight Management Context

Appetite and weight management is where retatrutide has generated the most attention — and for good reason. The Phase 2 data represents a step-change in what pharmaceutical weight loss can achieve:[1]

• 24.2% mean weight loss at 48 weeks (12 mg dose) — unprecedented for any anti-obesity medication.[1]
• 100% of 12 mg participants lost ≥5% body weight; 83% lost ≥15%; 63% lost ≥20%.[1]
• Weight loss trajectory still descending at 48 weeks — the full plateau had not been reached, suggesting even greater reductions with longer treatment.[1]

For comparison within the incretin agonist class:

• Liraglutide (Saxenda): ~8% mean weight loss
• Semaglutide (Wegovy): ~15-17% mean weight loss
• Tirzepatide (Zepbound): ~20-22% mean weight loss
• Retatrutide: up to 24.2% mean weight loss — and still declining at study end

The honest caveat: these are Phase 2 results. Phase 3 trials (TRIUMPH) are underway and will provide the definitive efficacy and safety data needed for FDA approval. Phase 2 results don’t always replicate exactly in Phase 3, though the consistency across the obesity and T2D cohorts is encouraging. See Retatrutide vs Tirzepatide for the detailed comparison.[1][2][6]

Fat Loss and Body Recomp Context

Fat loss and body recomposition is where retatrutide’s triple agonist mechanism may offer a genuine advantage over dual and single agonists.

• Body composition data: Coskun et al. (2025) published a dedicated body composition substudy in Lancet Diabetes & Endocrinology, examining DEXA-measured changes in fat mass and lean mass with retatrutide in people with type 2 diabetes.[5]
• Glucagon-driven fat oxidation: the glucagon receptor component specifically promotes hepatic and systemic fat oxidation and thermogenesis — mechanisms that target fat mass reduction beyond what appetite suppression alone achieves.[7][8]
• Liver fat reduction: the Sanyal MASLD trial showed up to 82.4% liver fat reduction — a direct demonstration of the glucagon component’s effect on ectopic fat stores. This degree of hepatic fat clearance has not been achieved by any single or dual agonist.[3]

The lean mass question: like all GLP-1-class compounds, retatrutide-induced weight loss includes some lean mass component. Whether the glucagon receptor’s metabolic effects alter the fat-to-lean-mass loss ratio favourably compared to semaglutide or tirzepatide is being evaluated in Phase 3. Resistance exercise remains the most evidence-based strategy for preserving lean mass during pharmacological weight loss.

Metabolic Health and Insulin Sensitivity Context

Metabolic health and insulin sensitivity is retatrutide’s second major clinical domain, with particularly strong signals in liver health and glycaemic control.[2][3]

• Glycaemic control: Rosenstock et al. (2023) demonstrated HbA1c reductions of up to 2.0% in patients with type 2 diabetes — comparable to or exceeding other incretin-based therapies. Nearly all participants on higher doses achieved HbA1c targets.[2]
• MASLD/liver fat clearance: Sanyal et al. (2024) showed 82.4% liver fat reduction and 93% of participants meeting the ≥30% threshold associated with MASLD resolution. This is the strongest liver fat reduction data for any incretin-class compound — a direct result of the glucagon receptor component.[3]
• Insulin sensitivity improvement: the combination of substantial weight loss, visceral/hepatic fat reduction, and direct metabolic receptor activation produces multi-pathway insulin sensitivity improvement.[2][4]
• Cardiometabolic markers: systematic reviews have confirmed improvements across lipid profiles, blood pressure, and inflammatory markers alongside weight and glucose improvements.[4][10]

The liver health finding is clinically significant: MASLD/MASH (formerly NAFLD/NASH) affects approximately 30% of the global population and is becoming the leading cause of liver transplantation. A compound that can reduce liver fat by >80% while also addressing obesity and diabetes could represent a transformative treatment approach for overlapping cardiometabolic conditions.[3]

Retatrutide Benefits

Retatrutide benefits based on available Phase 2 evidence:

• Unprecedented weight loss magnitude: up to 24.2% mean body weight reduction at 48 weeks — the largest for any anti-obesity medication in controlled trials, and still declining at study end.[1]
• Triple receptor mechanism: unique glucagon receptor component adds energy expenditure and fat oxidation pathways beyond appetite suppression, targeting fat mass through both intake reduction and output increase.[7][8]
• Extraordinary liver fat reduction: up to 82.4% liver fat clearance in the MASLD trial — the strongest hepatic fat reduction of any incretin-class compound.[3]
• Robust glycaemic improvement: HbA1c reductions of up to 2.0% in patients with type 2 diabetes.[2]
• Once-weekly dosing: consistent with other modern incretin agonists, supporting treatment adherence.[1][2]
• Multi-indication potential: Phase 3 TRIUMPH programme spans obesity, T2D, OSA, and osteoarthritis — the broadest indication pipeline of any single incretin agonist.[6]
• Consistent efficacy across cohorts: weight loss and metabolic improvement demonstrated in both obesity and T2D populations, meta-analysis confirmed.[1][2][4]

Important framing: all current retatrutide benefits data is from Phase 2 trials. While the results are exceptionally promising, FDA approval and full safety characterisation require Phase 3 completion. The TRIUMPH programme is expected to report results over the coming years.[6]

Retatrutide Side Effects

For retatrutide side effects intent (search volume: 6,600), the safety profile is based on Phase 2 data with hundreds of participants, not yet the thousands typical of Phase 3:[1][2][11]

• Gastrointestinal effects (most common): nausea, diarrhoea, vomiting, and constipation — consistent with the GLP-1 receptor agonist class. In the NEJM Phase 2 trial, GI events were generally mild to moderate and most common during dose escalation. Incidence was dose-dependent.[1]
• Decreased appetite: reported frequently, though this is more of an intended pharmacological effect than a side effect per se.[1][2]
• Injection site reactions: generally mild.[1]
• Heart rate increase: small mean increases in heart rate observed, consistent with other GLP-1 agonists.[1][2]
• Glucagon-specific considerations: the glucagon receptor component theoretically increases hepatic glucose output, which could counteract the glucose-lowering effects in some contexts. In practice, the Phase 2 T2D trial showed net glycaemic improvement, suggesting the GLP-1/GIP components compensate effectively.[2][7]

What we don’t know yet:

• Long-term safety: the longest Phase 2 exposure is 48 weeks. Multi-year safety data will come from Phase 3 (TRIUMPH).[6]
• Cardiovascular outcomes: no dedicated CVOT has been completed for retatrutide. This will likely be required for full regulatory characterisation.
• Rare events: uncommon adverse events (pancreatitis, thyroid signals, gallbladder events) require larger Phase 3 populations to characterise properly.
• Glucagon receptor long-term effects: sustained glucagon receptor agonism is novel in this context. Any unexpected hepatic, metabolic, or body composition effects may only emerge with longer exposure.[8][9]

The honest assessment: the Phase 2 safety profile appears manageable and broadly consistent with the GLP-1 agonist class, but the compound is genuinely novel (no triple agonist has been approved before), and caution is warranted until Phase 3 data is available.[1][4][11]

Half-Life

Retatrutide has a plasma half-life of approximately 6 days, enabling once-weekly subcutaneous administration. This is comparable to other modern incretin agonists:[7]

• Liraglutide: ~13 hours (daily injection)
• Semaglutide: ~7 days (weekly injection)
• Tirzepatide: ~5 days (weekly injection)
• Retatrutide: ~6 days (weekly injection)

The ~6-day half-life provides sustained receptor activation across all three targets (GLP-1, GIP, glucagon) throughout the dosing interval, maintaining the coordinated metabolic effects between weekly injections.[7]

TRIUMPH Phase 3 Programme

The TRIUMPH clinical programme represents the most ambitious development plan for any single incretin agonist, spanning multiple obesity-related indications:[6]

• TRIUMPH-1: obesity without diabetes
• TRIUMPH-2: obesity with type 2 diabetes
• TRIUMPH-3: obesity with obstructive sleep apnoea
• TRIUMPH-4: obesity with knee osteoarthritis

Giblin et al. (2026) published the rationale and design of the TRIUMPH registration programme in Diabetes, Obesity and Metabolism, detailing the Phase 3 trial structures that will generate the data necessary for FDA approval decisions.[6]

Timeline context: if Phase 3 results are positive, retatrutide could potentially reach FDA approval in 2027-2028, though regulatory timelines are inherently uncertain. The breadth of the TRIUMPH programme reflects Eli Lilly’s confidence in the compound based on Phase 2 results.

Limits of Current Evidence

• No approved indication. Retatrutide is investigational. All clinical data comes from Phase 2 trials (hundreds of participants, not thousands). Phase 3 is underway but not yet reported.[1][6]
• No long-term safety data beyond 48 weeks. The longest exposure in published trials is 48 weeks. Multi-year safety characterisation requires Phase 3 completion.[1][2]
• No cardiovascular outcome trial. Unlike semaglutide (SELECT) and liraglutide (LEADER), retatrutide has no completed CVOT. This is a significant evidence gap for a compound targeting cardiometabolic populations.
• Novel mechanism, unknown unknowns. No triple GLP-1/GIP/glucagon agonist has been approved before. Sustained glucagon receptor activation in combination with incretin agonism is pharmacologically unprecedented, and unexpected effects may emerge with larger populations and longer exposure.[7][8]
• Cross-trial comparisons are indirect. Retatrutide has not been compared head-to-head with tirzepatide or semaglutide in a single trial. The “24% vs 22% vs 17%” weight loss framing compares across different trials with different populations and designs.[1]
• Phase 2 results may not fully replicate. Phase 3 trials have stricter inclusion criteria, larger populations, and longer follow-up. Results sometimes differ from Phase 2.

Decision rule: retatrutide’s Phase 2 data is the strongest of any anti-obesity medication at this development stage, published in the highest-quality journals (NEJM, Lancet, Nature Medicine). But it remains investigational, and the evidence gap between “promising Phase 2” and “approved with long-term safety data” is substantial.

Verdict

Retatrutide represents the most ambitious evolution of the incretin agonist class — the first triple GLP-1/GIP/glucagon receptor agonist with clinical data. Its Phase 2 results (24.2% weight loss, 82.4% liver fat reduction, 2.0% HbA1c improvement) are the strongest ever reported for any single anti-obesity compound in controlled trials.[1][2][3]

The glucagon receptor component is the key differentiator. It introduces energy expenditure and hepatic fat oxidation mechanisms that go beyond appetite suppression, creating a “reduce intake + increase output” approach that may explain the superior weight loss magnitude compared to dual agonists like tirzepatide.[7][8]

The critical caveat: retatrutide is not yet approved, has no long-term safety data, and the Phase 3 TRIUMPH programme must confirm these results before clinical use can be evaluated. The compound’s position in this guide is as the most promising investigational candidate in the incretin class — extraordinary Phase 2 evidence, but still investigational. See Retatrutide vs Tirzepatide for the detailed positioning against the current best-in-class approved dual agonist.

For navigation, map this profile to Appetite & Weight Management, Fat Loss & Recomp, and Metabolic Health / Insulin Sensitivity. Cross-reference with Tirzepatide, Semaglutide, and Liraglutide for full class context.

FAQ

What is retatrutide?

Retatrutide (LY3437943) is a first-in-class investigational triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it produced the largest weight loss ever reported for any anti-obesity medication in Phase 2 trials (up to 24.2% at 48 weeks). It is currently in Phase 3 trials (TRIUMPH programme) but not yet FDA-approved.[1][6][7]

What does retatrutide do?

Retatrutide reduces appetite (via GLP-1/GIP receptors), improves glycaemic control (via GLP-1-mediated insulin secretion), and increases energy expenditure and fat oxidation (via glucagon receptor). Phase 2 trials demonstrated 24.2% body weight loss, 82.4% liver fat reduction, and HbA1c reductions of up to 2.0%.[1][2][3]

What are retatrutide side effects?

The most common side effects in Phase 2 trials were gastrointestinal: nausea, diarrhoea, vomiting, and constipation — consistent with the GLP-1 agonist class. These were generally mild to moderate and most common during dose escalation. Long-term safety data beyond 48 weeks is not yet available. Phase 3 will characterise rare events and the long-term effects of sustained glucagon receptor activation.[1][2]

Is retatrutide FDA approved?

No. Retatrutide is currently investigational and in Phase 3 clinical trials (the TRIUMPH programme). If Phase 3 results are positive, FDA approval could potentially occur around 2027-2028. It has not been approved for any indication in any country.[6]

How does retatrutide compare to tirzepatide?

Both are Eli Lilly compounds. Tirzepatide is a dual GIP/GLP-1 agonist (FDA-approved as Mounjaro/Zepbound); retatrutide adds a third target — the glucagon receptor. In cross-trial comparisons, retatrutide’s 24.2% weight loss exceeds tirzepatide’s ~20-22%, though no head-to-head trial exists yet. See Retatrutide vs Tirzepatide for the detailed comparison.[1][7]

How does retatrutide compare to semaglutide?

Semaglutide (Wegovy/Ozempic) is a single GLP-1 agonist producing ~15-17% weight loss. Retatrutide activates three receptors (GLP-1 + GIP + glucagon) and produced up to 24.2% weight loss in Phase 2. However, semaglutide is FDA-approved with extensive safety data including a cardiovascular outcomes trial (SELECT), while retatrutide remains investigational.[1]

Why is the glucagon receptor important?

Glucagon receptor activation increases hepatic fat oxidation, stimulates thermogenesis, and raises energy expenditure. This creates a “dual mechanism” for weight loss: GLP-1/GIP reduce caloric intake through appetite suppression, while glucagon increases caloric output through metabolic activation. This combination likely explains retatrutide’s superior weight loss and extraordinary liver fat reduction results.[3][7][8]

Retatrutide dose and retatrutide dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Retatrutide is an investigational compound not approved for any indication. Phase 2 trials evaluated doses from 0.5 mg to 12 mg weekly. This profile focuses on mechanism context, evidence quality, and risk-aware interpretation.

How much weight can you lose on retatrutide?

In the Phase 2 NEJM trial, the highest dose (12 mg weekly) produced 24.2% mean body weight loss at 48 weeks. 83% of participants lost ≥15% and 63% lost ≥20%. The weight loss trajectory was still descending at 48 weeks, suggesting even greater losses with longer treatment. These are Phase 2 results; Phase 3 will provide definitive efficacy data.[1]

Does retatrutide help with fatty liver?

Yes — the Phase 2a MASLD trial (Sanyal 2024, Nature Medicine) showed up to 82.4% liver fat reduction from baseline, with 93% of participants meeting the clinically meaningful ≥30% threshold. This is the strongest liver fat reduction data for any incretin-class compound, likely driven by the glucagon receptor component’s direct effects on hepatic fat oxidation.[3]

When will retatrutide be available?

Retatrutide is in Phase 3 clinical trials (TRIUMPH programme). If results are positive and regulatory submission proceeds smoothly, approval could potentially occur around 2027-2028. Regulatory timelines are inherently uncertain and depend on Phase 3 results, safety data, and regulatory review processes.[6]

Is retatrutide safe?

Phase 2 data shows a safety profile broadly consistent with the GLP-1 agonist class (primarily GI side effects). However, long-term safety data beyond 48 weeks is not yet available, and the glucagon receptor component is pharmacologically novel. Phase 3 trials with larger populations and longer follow-up will provide the definitive safety characterisation. Caution is warranted for any investigational compound without full regulatory review.[1][2][6]

References

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.
2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID: 37385280.
3. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(8):2292-2300. PMID: 38858523.
4. Pasqualotto E, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabol Open. 2024;24:100313. PMID: 39318607.
5. Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2025;13(7):527-537. PMID: 40609566.
6. Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registration programme. Diabetes Obes Metab. 2026;28(2):e70089. PMID: 41090431.
7. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PMID: 35985340.
8. Katsi V, et al. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(7):935. PMID: 40563436.
9. Abdul-Rahman T, et al. The power of three: Retatrutide’s role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024;984:177068. PMID: 39515565.
10. Abdrabou Abouelmagd A, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis. Proc (Bayl Univ Med Cent). 2025;38(3):361-368. PMID: 40291085.
11. Kaur M, et al. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol. 2024;80(5):621-632. PMID: 38367045.